Jonathan C. Javitt, Chairman and Chief Scientist, 10% Owner at NRX Pharmaceuticals, Inc. (NRXP), bought 40,000 shares at $1.17 ($47K) on 2024-12-17, disclosed to the SEC on 2024-12-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| Filing → |
| NRXP | SELL | 2022-12-09 | $400K | — | Filing → |
| NRXP | BUY | 2022-06-02 | $5.8M | — | Filing → |
| NRXP | BUY | 2022-06-02 | $116K | — | Filing → |